This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.
Voluntary signing of informed consent.
Age ≥ 18 years, no gender restriction.
Histologically confirmed follicular lymphoma (grades 1-3a), CD20 positive by immunohistochemistry.
No prior systemic treatment for FL.
History of allergy to any component of monoclonal antibodies or investigational drugs.
Central nervous system involvement.
History of previous malignant tumors.
Clinically significant cardiac or pulmonary diseases.
Sun Yat-sen University
Lead sponsor
Gansu Cancer Hospital
Collaborator
Ganzhou Cancer Hospital
Collaborator
Fifth Affiliated Hospital, Sun Yat-Sen University
Collaborator
Fifth Affiliated Hospital of Guangzhou Medical University
Collaborator